Plain-English translation of NCT07068763 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for early rectal cancer that combines three components: focused radiation aimed only at the tumor (not surrounding lymph nodes), (a chemotherapy pill), and PD-1/CTLA-4 inhibitors (immune-boosting drugs that help your body fight cancer). The goal is to shrink the tumor enough that some patients may avoid surgery entirely and keep their rectum functioning normally.
Many rectal cancer patients need surgery that removes part of the rectum and creates a permanent colostomy (a surgically created opening for bowel movements). This trial exists because early research suggests that this new medication combination might help shrink tumors so well that more patients could avoid surgery altogether, preserve their normal bowel function, and experience fewer side effects from radiation.
You likely qualify if…
You likely don't qualify if…
You would receive 5 days of focused radiation therapy to your tumor. Eight days later, you would start taking a chemotherapy pill twice daily for two weeks, along with intravenous immune-boosting drug infusions given every three weeks for four cycles total. Two weeks after finishing treatment, you would have imaging tests to see how well your tumor responded. If your cancer disappears completely, you would enter a watch-and-wait program with regular monitoring. If your tumor doesn't fully respond, you would discuss surgery options with your care team.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China